UCB SA (OTCMKTS:UCBJY – Get Free Report) shares passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $96.49 and traded as low as $93.22. UCB shares last traded at $93.50, with a volume of 9,796 shares changing hands.
UCB Stock Performance
The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The company’s 50 day simple moving average is $96.48 and its 200-day simple moving average is $91.45.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Oracle Announces Game-Changing News for the AI Industry
- The How and Why of Investing in Gold Stocks
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
